DNA (recombinant human telomerase-specific replication-competent oncolytic adenovirus 5 vector OBP-301)
Melanoma Stage III
Syneos Healthgene_therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
450 Active assets in the Melanoma Stage III cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gm-Csf Ultimovacs ASA | Phase 4 | BBB |
Sargramostim Mayo Clinic | Phase 3 | BBB |
Cediranib M.D. Anderson Cancer Center | Phase 3 | BBB |
Ifa Craig L Slingluff, Jr | Phase 2 | BB |
DACARBAZINE Suzhou BlueHorse Therapeutics Co., Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
DNA (recombinant human telomerase-specific replication-competent oncolytic adenovirus 5 vector OBP-301) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →